Drugs

New Pathway Sought for Albuterol Inhalation Aerosol Products

An 8/4 petition submitted by a Matthew Arp (no affiliation or organization listed) asks FDA to create a continuation access pathway, not unrestricted shelf access, for adults with a prior albuterol sulfate inhalation aerosol prescription or clinician-diagnosed airway disease. The petition says the nonprescription product would remain subject to an FDA-approved additional condition for nonprescription use (ACNU), with pharmacist or equivalent screening, while prescription products remain available in parallel for insurance coverage and conventional care.

“This petition does not ask FDA to authorize immediate marketing without a product application,” the document says, “to eliminate the prescription channel, to permit diagnosis of new respiratory disease through self-treatment, or to make albuterol available through unrestricted retail shelving. It asks FDA to use its express rulemaking authority and its current ACNU framework to remove a recurrent access barrier without discarding safeguards.

The petition asks that FDA take these specific actions:

open notice-and-comment rulemaking to determine that conventional prescription dispensing requirements are not necessary to protect public health for the limited nonprescription conditions when a product is approved with an ACNU;
publish proposed regulatory text initially covering albuterol sulfate as the sole active ingredient in a metered dose oral inhalation aerosol delivering 90 micrograms of albuterol base per actuation for adults aged 18 and older who can verify a prior albuterol prescription or a clinician-diagnosed condition for which albuterol is indicated;
require that any nonprescription product use a separate approved NDA or ANDA and an FDA-approved ACNU;
preserve simultaneous marketing of prescription albuterol products;
issue a Federal Register request for information and convene an advisory committee or establish another public advisory process to evaluate the proposed eligibility criteria, screening thresholds, labeling, human factors evidence, postmarketing measures, health equity effects, and environmental issues;
invite and provide regulatory guidance to holders of albuterol NDAs and other prospective applicants concerning the data package for a separate ACNU application; and
if FDA determines that the current record does not support immediate publication of a final rule, grant the petition in part by initiating the public proceeding, identifying the specific evidentiary gaps that must be closed, permitting supplementation and describing a staged continuation-access pathway for adults with a verified prior prescription.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome